Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer
Figure 5
RASSF1A and RASSF2A methylation profiles in different N stages. Percentage of RASSF1A methylation had a range of 50–87.5% in different N stage, and percentage of RASSF2A had range of 0% −11%. Aberrant methylation of RASSF1A and RASSF2A promotor showed no relationship to lymph node metastasis.
